Literature DB >> 27630873

Morphometric Analysis of Peripapillary Thickness in Hypertensives and Normotensives using Optical Coherence Tomography (OCT).

Krishna Rao Addoor1, Sulatha V Bhandary2, Lavanya G Rao3, Smita Kapoor4.   

Abstract

INTRODUCTION: Hypotension following antihypertensive treatment is associated with retinal nerve fibre loss. There are studies that have reported the changes in RNFL in hypertensives. AIM: To compare the Retinal Nerve Fibre Layer (RNFL) thickness using Optical Coherence Tomography (OCT) in hypertensive and normotensive individuals.
MATERIALS AND METHODS: The cross-sectional study was conducted from October 2012 to September 2014 to compare the RNFL thickness using SD OCT in hypertensive {no other ocular or systemic co-morbidity, vision better or equal to 6/9 (n=30)} and normotensive (n=30) individuals.
RESULTS: Statistically significant RNFL loss was detected in hypertensives (98.31 ± 7.01) when compared to the normotensives (102.51 ± 8.72) p=0.001.
CONCLUSION: Significant loss of RNFL in hypertensives point towards the altered autoregulation and warrants larger studies to assess the clinical relevance.

Entities:  

Keywords:  Hypertensive versus normotensives; Intra ocular pressure; OCT RNFL loss

Year:  2016        PMID: 27630873      PMCID: PMC5020270          DOI: 10.7860/JCDR/2016/18642.8105

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  19 in total

1.  Regulation of optic nerve head blood flow in normal tension glaucoma patients.

Authors:  C J Pournaras; C E Riva; H Bresson-Dumont; P De Gottrau; A Bechetoille
Journal:  Eur J Ophthalmol       Date:  2004 May-Jun       Impact factor: 2.597

Review 2.  Blood pressure and glaucoma.

Authors:  V P Costa; E S Arcieri; A Harris
Journal:  Br J Ophthalmol       Date:  2009-03-30       Impact factor: 4.638

Review 3.  Relationships among systemic blood pressure, intraocular pressure, and open-angle glaucoma.

Authors:  Sunil Deokule; Robert N Weinreb
Journal:  Can J Ophthalmol       Date:  2008-06       Impact factor: 1.882

4.  Association of blood pressure status with the optic disk structure in non-glaucoma subjects: the Thessaloniki eye study.

Authors:  Fotis Topouzis; Anne L Coleman; Alon Harris; Christian Jonescu-Cuypers; Fei Yu; Leonidas Mavroudis; Eleftherios Anastasopoulos; Theofanis Pappas; Archimidis Koskosas; M Roy Wilson
Journal:  Am J Ophthalmol       Date:  2006-07       Impact factor: 5.258

5.  Quantification of nerve fiber layer thickness in normal and glaucomatous eyes using optical coherence tomography.

Authors:  J S Schuman; M R Hee; C A Puliafito; C Wong; T Pedut-Kloizman; C P Lin; E Hertzmark; J A Izatt; E A Swanson; J G Fujimoto
Journal:  Arch Ophthalmol       Date:  1995-05

6.  Blood pressure, perfusion pressure, and open-angle glaucoma: the Los Angeles Latino Eye Study.

Authors:  Farnaz Memarzadeh; Mei Ying-Lai; Jessica Chung; Stanley P Azen; Rohit Varma
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-01-20       Impact factor: 4.799

7.  Glaucoma is associated with peripheral vascular endothelial dysfunction.

Authors:  Wei-Wen Su; Shih-Tsung Cheng; Wan-Jing Ho; Pei-Kwei Tsay; Shiu-Chen Wu; Shirley H L Chang
Journal:  Ophthalmology       Date:  2008-02-20       Impact factor: 12.079

8.  Blood flow in the human optic nerve head during isometric exercise.

Authors:  A Movaffaghy; S R Chamot; B L Petrig; C E Riva
Journal:  Exp Eye Res       Date:  1998-11       Impact factor: 3.467

9.  Systemic antihypertensive medication and incident open-angle glaucoma.

Authors:  Rogier P H M Müskens; Simone de Voogd; Roger C W Wolfs; Jacqueline C M Witteman; Albert Hofman; Paulus T V M de Jong; Bruno H C Stricker; Nomdo M Jansonius
Journal:  Ophthalmology       Date:  2007-06-12       Impact factor: 12.079

10.  Detection of glaucoma progression by assessment of segmented macular thickness data obtained using spectral domain optical coherence tomography.

Authors:  Jung Hwa Na; Kyung Rim Sung; Seunghee Baek; Yoon Jeon Kim; Mary K Durbin; Hye Jin Lee; Hwang Ki Kim; Yong Ho Sohn
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-06-20       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.